Idera to Present at the Stifel 2016 Healthcare Conference
November 10 2016 - 7:30AM
Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage
biopharmaceutical company developing toll-like receptor and RNA
therapeutics for patients with cancer and rare diseases, today
announced that Idera’s Chief Executive Officer, Vincent Milano will
provide a corporate overview the Stifel 2016 Healthcare Conference
on Wednesday November 16, 2016 at 3:00 p.m. Eastern Time at the
Lotte New York Palace Hotel.
Live audio webcast of Idera’s presentations will be accessible
in the Investors and Media section of Idera’s website at
http://www.iderapharma.com. Archived versions will also be
available on the Company’s website after the event for 90
days.
About Idera Pharmaceuticals Idera
Pharmaceuticals is a clinical-stage biopharmaceutical company
developing novel nucleic acid-based therapies for the treatment of
certain cancers and rare diseases. Idera’s proprietary technology
involves designing synthetic oligonucleotide-based drug candidates
to modulate the activity of specific TLRs. In addition to its TLR
programs, Idera has used its proprietary knowledge to create a
third generation antisense technology platform which inhibits the
production of disease-associated proteins by targeting RNA. To
learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact
Robert Doody
VP, IR & Corporate Communications
617-679-5515 (office)
484‐639‐7235 (mobile)
rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024